rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Paul L. Berns

Director and Officer

Company insider

Files Form 4 as: Director and Officer, Neumora Therapeutics; Director and 10% owner, Kardigan; 10% owner, Lyell Immunopharma; Director, Metsera; Director, Unity Biotechnology; Director, EQRx; Director, Jazz Pharmaceuticals; Director, Yarrow Bioscience.

Every Form 4 they filed

In numbers

Trades disclosed
265
Buys
7
Sells
41
Bought
$67.0M
Sold
$25.1M
Companies
12
Companies where not an officer
9
First trade
13 Apr 2006
Last trade
20 Aug 2026
Last filed
21 Aug 2026

Companies traded

Where they are an officer
NMRA Neumora TherapeuticsDirector, Officer · Biotechnology · last 20 Aug 20260 buys · 2 sells
Anacor PharmaceuticalsDirector, Officer · last 24 Jun 20160 buys · 9 sells
Allos TherapeuticsOfficer · last 4 Sep 20123 buys · 16 sells
Everywhere else they filed: board seats, 10% stakes, other companies
KARD KardiganDirector, 10% owner · Biotechnology · last 22 Jun 20261 buy · 0 sells
LYEL Lyell Immunopharma10% owner · Biotechnology · last 6 Mar 20261 buy · 0 sells
MetseraDirector · last 13 Nov 20251 buy · 0 sells
Unity BiotechnologyDirector · last 21 Jun 20240 buys · 0 sells
EQRxDirector · last 9 Nov 20230 buys · 0 sells
JAZZ Jazz PharmaceuticalsDirector · Pharmaceuticals · last 5 Aug 20210 buys · 11 sells
YARW Yarrow BioscienceDirector · Biotechnology · last 25 Jun 20190 buys · 0 sells
XenoportDirector · last 17 May 20160 buys · 3 sells
CLRB Cellectar BiosciencesDirector · Biotechnology · last 20 Apr 20161 buy · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
20 Aug 2026filed 21 Aug 2026NMRA Neumora Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—500,000 at $0.00filing
20 Aug 2026filed 21 Aug 2026NMRA Neumora Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—500,000 at $0.00filing
22 Jun 2026filed 24 Jun 2026KARD KardiganBiotechnologySEC FORM 4 Bought$20.0M1,250,000 at $16.00filing
22 Jun 2026filed 24 Jun 2026KARD KardiganBiotechnologySEC FORM 4 Bought$20.0M1,250,000 at $16.00filing
17 Jun 2026filed 22 Jun 2026KARD KardiganBiotechnologySEC FORM 4 Code C—13,792,035filing
17 Jun 2026filed 22 Jun 2026KARD KardiganBiotechnologySEC FORM 4 Code A—20,706 at $0.00filing
17 Jun 2026filed 22 Jun 2026KARD Kardiganoption or derivative · BiotechnologySEC FORM 4 Code C—5,148,587filing
17 Jun 2026filed 22 Jun 2026KARD Kardiganoption or derivative · BiotechnologySEC FORM 4 Code C—5,148,587filing
17 Jun 2026filed 22 Jun 2026KARD Kardiganoption or derivative · BiotechnologySEC FORM 4 Code C—1,204,000filing
17 Jun 2026filed 22 Jun 2026KARD Kardiganoption or derivative · BiotechnologySEC FORM 4 Code C—2,306,401filing
17 Jun 2026filed 22 Jun 2026KARD Kardiganoption or derivative · BiotechnologySEC FORM 4 Code C—1,204,000filing
17 Jun 2026filed 22 Jun 2026KARD Kardiganoption or derivative · BiotechnologySEC FORM 4 Code C—2,306,401filing
17 Jun 2026filed 22 Jun 2026KARD KardiganBiotechnologySEC FORM 4 Code C—13,792,035filing
17 Jun 2026filed 22 Jun 2026KARD KardiganBiotechnologySEC FORM 4 Code A—20,706 at $0.00filing
6 Mar 2026filed 9 Mar 2026LYEL Lyell ImmunopharmaBiotechnologySEC FORM 4 Bought$12.5M488,090 at $25.61filing
17 Feb 2026filed 19 Feb 2026NMRA Neumora TherapeuticsBiotechnologySEC FORM 4 Sold$34K9,819 at $3.51filing
17 Feb 2026filed 19 Feb 2026NMRA Neumora TherapeuticsBiotechnologySEC FORM 4 Sold$34K9,819 at $3.51filing
8 Jan 2026filed 9 Jan 2026NMRA Neumora Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—1,650,000 at $0.00filing
8 Jan 2026filed 9 Jan 2026NMRA Neumora Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—1,650,000 at $0.00filing
13 Nov 2025filed 13 Nov 2025Metseraoption or derivativeSEC FORM 4 Code A—4,031filing

Sectors

Health Care16
Not placed32

Buys in green, sells in red, by the company’s sector.

Related people

Michael Lee MilliganOfficer · Officer at Neumora Therapeutics, filing Form 4 there in the last year
Jason DuncanOfficer · Officer at Neumora Therapeutics, filing Form 4 there in the last year
Daljit Singh AuroraOfficer · Officer at Neumora Therapeutics, filing Form 4 there in the last year
Joshua PintoPresident & CEO · President & CEO at Neumora Therapeutics, filing Form 4 there in the last year
David PiacquadDirector · Director at Neumora Therapeutics, filing Form 4 there in the last year
Jarrad Mattieu AguirreChief Medical Officer · Also traded LYEL in the last 90 days
Renee D. GalaPresident & CEO · Also traded JAZZ in the last 90 days
Bruce C. CozaddDirector · Also traded JAZZ in the last 90 days